Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now displays a 403 Forbidden error page with a 403 header and a Home button, indicating restricted access to the study record rather than an ordinary content update.SummaryDifference21%

- Check12 days agoChange DetectedThe page footer now displays the site revision as v3.7.0, replacing the previous v3.6.6, reflecting a software revision update.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6. This indicates a minor update to the page version and routine maintenance rather than any visible content change.SummaryDifference0.0%

- Check34 days agoChange DetectedA new line '2016 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, recording NIH funding information. This addition provides funding attribution for the ARROW trial within the study record.SummaryDifference0.0%

- Check48 days agoChange DetectedFooter revision label updated from v3.6.4 to v3.6.5, indicating a software update.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, signaling a recent software release update for the page. This is an internal update rather than a change to study data or content.SummaryDifference0.0%

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.